All In Biotech

Drug Trial Radar · NCT06963034

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization

Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

284

Planned (sponsor's estimate)

Start

May 8, 2025

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
May 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

Conditions

  • Schizophrenia

Interventions

  • NBI-1117568Drug

    NBI-1117568 will be administered per schedule specified in the arm description.

  • PlaceboDrug

    Placebo will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5Time frame: Baseline, Week 5

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Bryant, Arkansas · Recruiting

  • Neurocrine Clinical Site

    Little Rock, Arkansas · Recruiting

  • Neurocrine Clinical Site

    Anaheim, California · Recruiting

  • Neurocrine Clinical Site

    Pico Rivera, California · Recruiting

  • Neurocrine Clinical Site

    San Diego, California · Recruiting

  • Neurocrine Clinical Site

    Sherman Oaks, California · Recruiting

  • Neurocrine Clinical Site

    Torrance, California · Recruiting

  • Neurocrine Clinical Site

    Hollywood, Florida · Recruiting

  • Neurocrine Clinical Site

    Miami Lakes, Florida · Recruiting

  • Neurocrine Clinical Site

    Atlanta, Georgia · Recruiting

  • Neurocrine Clinical Site

    Decatur, Georgia · Recruiting

  • Neurocrine Clinical Site

    Snellville, Georgia · Recruiting

  • Neurocrine Clinical Site

    Chicago, Illinois · Recruiting

  • Neurocrine Clinical Site

    Gaithersburg, Maryland · Recruiting

  • Neurocrine Clinical Site

    Watertown, Massachusetts · Recruiting

  • Neurocrine Clinical Site

    Marlton, New Jersey · Recruiting

  • Neurocrine Clinical Site

    Staten Island, New York · Recruiting

  • Neurocrine Clinical Site

    The Bronx, New York · Recruiting

  • Neurocrine Clinical Site

    Austin, Texas · Recruiting

  • Neurocrine Clinical Site

    DeSoto, Texas · Recruiting

  • Neurocrine Clinical Site

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.